In February 2020, both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease.
Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. Shares are down 65% since their peak. (tipranks.com)
Analyst...
Resistance breakout with higher lows and higher highs recently. Company is enjoying success with expansion of its Niobe system products in France. There is a inverted head and shoulders reversal pattern.
Q4 investor conference on 2/25 4:30PM EST at ir.stereotaxis.com
Stereotaxis is a healthcare technology and innovation leader in the development of robotic...